Skip to main content
. 2017 Oct 19;8:179–190. doi: 10.2147/LCTT.S139647

Table 4.

Sequential therapy

Second-line treatment, n (%) nab-Paclitaxel plus carboplatin
(n = 26)
Gemcitabine plus carboplatin
(n = 61)
Docetaxel 1 (4) 24 (39)
Gemcitabine 9 (35) 1 (2)
Paclitaxel plus carboplatin 3 (12) 7 (11)
Paclitaxel 2 (8) 7 (11)
nab-Paclitaxel plus carboplatin 8 (13)
Other 11 (42) 14 (23)